Combination of stem cell research and immunotherapy in gynecologic cancer

我们注意到CD133是卵巢癌的干细胞标记物。本研究旨在评估CD133+细胞在卵巢YST细胞系中的肿瘤形成能力，并检查CD133+细胞的特征，如细胞生长和侵袭性。我们的数据表明卵巢YST可能是由一小部分表达细胞表面标记物CD133的癌症干细胞样细胞维持的。CXCR4在NOY1-CD133+细胞中的表达水平明显高于CD133- NOY1细胞。与CD133-相比，nol1 -CD133+表达的CD44水平略高。我们还检测了GPC3在手术切除的卵巢癌组织中的表达。我们尝试免疫疗法治疗卵巢癌。我们检测了癌胎抗原GPC3的表达。我们的研究结果显示，51.6%的卵巢透明细胞癌肿瘤细胞中表达GPC3，尽管其他组织类型未染色，但GPC3在细胞内病变和细胞膜中均有表达，此外，我们发现90%的卵巢透明细胞癌肿瘤细胞中表达HLA-classI。我们证明了GPC3肽免疫治疗的有效性。我们启动了用于卵巢透明细胞腺癌患者的GPC3衍生肽疫苗的II期临床试验

We noticed CD133 as a stem cell marker in ovarian cancer. The present study was designed to evaluate the tumor-formation ability of CD133+ cells in ovarian YST cell lines and to examine characteristics of CD133+ cells such as cell growth, and invasiveness. Our data suggest that ovarian YST may be maintained by a rare fraction of cancer stem-like cells that express the cell surface marker CD133. CXCR4 levels were markedly higher in NOY1-CD133+ cells than CD133- NOY1 cells . NOY1-CD133+ expressed slightly higher levels of CD44 expression when compared with their CD133- counterparts.We also examined GPC3 expression in surgically resected ovarian carcinoma tissues. We tried immunotherapy in ovarian cancer. We investigated the expression ofonco-fetal antigen, GPC3. Our results showed that GPC3 was expressed in tumor cells from 51.6% of ovarian clear cell carcinoma although other histotypes were not stained, GPC3expression was observed in intracellular lesions as well as in the cell membrane, Furthermore, we showed that HLA-classI was expressed in tumor cells from 90% of ovarian clear cell carcinoma. We showed the validity of GPC3 peputide immunotherapy. We started a phase II clinical trial of the GPC3 derived peptide vaccine for ovarian clear cell adenocarcinoma patients